Importance of the field: Influenza represents a major sanitary and socio-economic burden and vaccination is universally considered the most effective strategy for preventing the disease and its complications. Traditional influenza vaccines have been on the market since the late 1940s, with million of doses administered annually worldwide, and demonstrated a substantial efficacy and safety. Areas covered in this review: The trivalent inactivated subunit vaccine has been available for more than 25 years and has been studied in healthy children, adults and the elderly and in people affected by underlying chronic medical conditions. We describe vaccine technology focusing on subunit vaccine production procedures and mode of action and provide updated information on efficacy and safety available data. What the reader will gain: A review of efficacy and safety data in healthy subjects and in high risk populations from major sponsor- and investigator-driven studies. Take home message: The vaccine showed a good immunogenicity and a favorable safety profile in all target groups. In the panorama of actually available influenza vaccines, trivalent inactivated subunit vaccine represents a well-established tool for preventing flu and the associated complications.
|Titolo:||Influvac, a trivalent inactivated subunit influenza vaccine|
|Parole Chiave:||children; influenza vaccine efficacy; influenza vaccine safety; influvac; trivalent subunit influenza vaccine|
|Settore Scientifico Disciplinare:||Settore MED/38 - Pediatria Generale e Specialistica|
|Data di pubblicazione:||gen-2011|
|Digital Object Identifier (DOI):||10.1517/14712598.2011.541436|
|Appare nelle tipologie:||01 - Articolo su periodico|